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Serum Cystatin C Concentrations in Cats with Hyperthyroidism and
Chronic Kidney Disease
T.L. Williams, H. Dillon, J. Elliott, H.M. Syme, and J. Archer
Background: Currently, no test can accurately predict the development of azotemia after treatment of hyperthyroidism.
Serum cystatin C concentrations (sCysC) might be less influenced by changes in body muscle mass and so better indicate the
presence of concurrent chronic kidney disease (CKD) in hyperthyroidism.
Hypotheses: sCysC will be higher in hyperthyroid cats that develop azotemia compared with hyperthyroid cats that
remain nonazotemic after treatment; sCysC will be higher in nonhyperthyroid cats with azotemic CKD than healthy older
cats and, sCysC will decrease after treatment of hyperthyroidism.
Animals: Ninety-one cats treated in first opinion practice.
Methods: Case–control study. sCysC were compared between hyperthyroid cats which developed azotemia within
4 months of successful treatment of hyperthyroidism (pre-azotemic group) and hyperthyroid cats which remained nona-
zotemic after treatment (nonazotemic group), and between nonhyperthyroid cats with azotemic CKD and healthy older cats.
sCysC were also compared between hyperthyroid cats before treatment and at time of establishment of euthyroidism. Data
are presented as median [25th, 75th percentile].
Results: Baseline sCysC were not different between the pre-azotemic and nonazotemic groups (1.9 [1.4, 2.3] mg/L versus
1.5 [1.1, 2.2] mg/L, respectively; P = .22). sCysC in nonhyperthyroid cats with azotemic CKD and healthy older cats were
not significantly different (1.5 [1.0, 1.9] mg/L versus 1.2 [0.8, 1.4] mg/L, respectively; P = .16). sCysC did not change signifi-
cantly after treatment of hyperthyroidism (pretreatment 1.8 [1.2, 2.3] mg/L, after treatment 1.6 [1.1, 2.4] mg/L; P = .82).
Conclusions and Clinical Importance: sCysC do not appear to be a reliable marker of renal function in hyperthyroid cats.
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Hyperthyroidism can complicate the diagnosis ofCKD, because it results in an increased glomerular
filtration rate (GFR)1 and decreased body muscle mass.2
This leads to a decrease in serum creatinine concentra-
tions, which can “mask” the presence of concurrent azo-
temic CKD in hyperthyroidism. As a result, many
hyperthyroid cats with CKD only develop azotemia
after treatment, once GFR and body muscle mass have
normalized. Currently, there is no single test that can
reliably predict the development of azotemia after treat-
ment for hyperthyroidism. Identification of hyperthyroid
cats with concurrent, but masked, CKD could be impor-
tant, because reliable information pretreatment could
influence the advice veterinarians give owners regarding
the treatment options and subsequent monitoring, to
avoid iatrogenic hypothyroidism,3 and would allow the
institution of appropriate treatment strategies for CKD.
Cystatin C is a low molecular weight protein which is
synthesized at a stable rate by most nucleated cells and
is freely filtered by the glomeruli,4 therefore, serum cys-
tatin C concentrations (sCysC) are inversely propor-
tional to GFR. Cystatin C could better reflect GFR in
hyperthyroidism because it is produced at a constant
rate by all nucleated cells, and therefore should be less
affected by changes in body muscle mass. However,
hyperthyroidism is also associated with increased sCysC
in hyperthyroid humans and cats,5,6 which could con-
found its use as a marker of GFR and concurrent
CKD. An automated particle enhanced turbidimetric
assay (PETIA) for the measurement of cystatin C was
recently validated for use in feline urine,7 however, the
PETIA used in the aforementioned study has not yet
been validated for the measurement of serum cystatin C
in cats. A human cystatin C particle-enhanced nephelo-
metric immunoassay (PENIA) was recently validated
for use in feline serum, and a small pilot study demon-
strated that serum cystatin C concentrations were
higher in cats with CKD than healthy control cats.8
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However, the PENIA requires the use of a specialized
immunonephelometer, whereas the PETIA can be per-
formed using standard automated analyzers available in
many commercial laboratories.
The first aim of this study was to validate a human
cystatin C PETIA for use in feline serum. Using this
assay, we then aimed to compare sCysC in hyperthyroid
cats, with and without concurrent, but masked, azote-
mic CKD, both before and after treatment, to evaluate
sCysC as a marker of CKD in hyperthyroidism.
Finally, we also compared sCysC between healthy older
cats and nonhyperthyroid cats with azotemic CKD, to
establish biological validity of the PETIA.
Methods
Validation of the PETIA for Measurement of Cystatin
C in Feline Serum
Serum cystatin C concentrations were measured by an auto-
mated analyzer (Olympus AU400, Beckman Coulter, High
Wycombe, UK) using a human PETIA method.a Precision of the
human PETIA was assessed by evaluating intra- and interassay
coefficients of variation (CV) for serum samples with low, medium,
and high concentrations of cystatin C. For intra-assay precision,
three replicates of each sample were evaluated within the same
run. For assessment of interassay variability, pooled feline serum
samples were evaluated in triplicate on 3 consecutive working
days. Specificity of the assay was assessed by serial dilution of a
serum sample with a high concentration of cystatin C with a
serum sample containing lower concentrations of cystatin C, to
avoid changes to the sample matrix. The limit of blank was deter-
mined by measurement of cystatin C concentrations in deionized
water (diH2O), which was evaluated in 5 samples on 3 consecutive
working days. The limit of blank was calculated as the mean inter-
polated cystatin C concentration in diH2O + 2 9 standard devia-
tion of the cystatin C concentration in diH2O.
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Clinical Study
Newly diagnosed nonazotemic (plasma creatinine concentration
<2.0 mg/dL) hyperthyroid cats (plasma total thyroxine (TT4)
>55 nmol/L) were recruited from 2 London-based first opinion
practices (People’s Dispensary for Sick Animals, Bow and the
Beaumont Sainsbury Animals’ Hospital, Camden) between March
2010 and June 2013. Blood and urine samples were collected from
these cats as part of a geriatric screening and healthcare pro-
gramme at the time of diagnosis with the consent of the owner.
The Ethics and Welfare Committee of the Royal Veterinary Col-
lege approved the diagnostic protocol. Jugular venous blood
samples were collected and placed in heparinized and nonanticoag-
ulated tubes, and urine samples collected by cystocentesis. Samples
were kept at 4°C before processing which occurred within 6 hours
of collection. Blood samples were centrifuged at 2016 9 g for
10 minutes to enable separation of plasma and serum from cellular
components. Heparinized plasma was submitted to a single exter-
nal laboratoryb for biochemical analysis including total thyroxine
concentrations (TT4). Residual serum was stored at 80°C until
batch analysis of sCysC. Residual serum was also used to measure
TT4 by enzyme immunoassay.10,c Urine samples underwent full in-
house urinalysis including measurement of urine specific gravity
(USG) by refractometry, dipstick analysis and urine sediment
examination. If bacteria or pyuria (>5 white blood cells/10009
field) was identified on sediment examination the patient was
excluded from the study. Hyperthyroid cats treated with glucocor-
ticoids were also excluded.
Hyperthyroid cats were treated with anti-thyroid medication
(carbimazole or methimazole) alone, or in combination with thy-
roidectomy, and were monitored for a 4 months period after suc-
cessful treatment of hyperthyroidism (TT4 < 40 nmol/L). Blood
and urine samples were obtained at the time of establishment of
euthyroidism and after this monitoring period. sCysC were mea-
sured at baseline and the time of establishment of euthyroidism
only (usually 4–8 weeks after starting treatment).c In hyperthyroid
cats, renal azotemia was defined as a plasma creatinine concentra-
tion >2.0 mg/dL (the upper limit of the first commercial labora-
toryb reference interval, derived in an internal unpublished study,
Federico Sacchini, personal communication) in conjunction with
inadequate urine concentrating ability (USG < 1.035), or persis-
tent azotemia on two or more consecutive occasions (usually
approximately 4 weeks apart) without evidence of a prerenal
cause. Hyperthyroid cats which developed azotemia within the
4 months follow-up period were defined as pre-azotemic, and
were presumed to have had concurrent, but masked, azotemic
CKD at the time of diagnosis. All other hyperthyroid cats were
defined as nonazotemic.
In addition, blood and urine samples were obtained from cats
at 3 UK first-opinion practices between March 2013 and April
2015, as part of a free-of-charge screening programme. Samples
from these practices were used to establish the healthy older cat
and nonhyperthyroid azotemic CKD groups. The Ethics and Wel-
fare Committee of the Department of Veterinary Medicine at the
University of Cambridge approved the diagnostic protocol (project
code CR56). To be included, cats had to be at least 8 years old,
and have no known major systemic diseases (eg cardiac disease,
diabetes mellitus, or hyperthyroidism). Exclusion criteria included
feeding of a low protein low phosphate (renal care) diet, recent or
ongoing treatment with corticosteroids, diuretics or angiotensin
converting enzyme inhibitors, and recent or concurrent intra-
venous fluid therapy at the time of sampling. Blood samples (in
EDTA and nonanticoagulated tubes) were taken by jugular
venepuncture and urine samples were taken by cystocentesis if pos-
sible. If cystocentesis was not possible, the owners were asked to
obtain a free-catch urine sample and submit it for analysis within
3 days of blood sampling. Blood and urine samples were submit-
ted to a commercial laboratoryc for complete blood count, serum
biochemistry including TT4 (by enzyme immunoassay)10 and uri-
nalysis including urine protein:creatinine ratio (UPC). Urinalysis
included measurement of USG by refractometry, urine dipstick,
and sediment analysis. Residual serum was stored at 80°C until
batch analysis of sCysC.c Cats were excluded from further analysis
if; TT4 was >40 nmol/L, there was evidence of bacteriuria, pyuria
(>5 white blood cells/10009 field), or gross hematuria, there was
evidence of severe systemic illness on hematology and biochem-
istry, or if the samples were more than 3 days old at the time of
sample analysis.
Nonhyperthyroid cats were classified as having azotemic CKD
if they had a serum creatinine concentration >1.7 mg/dL (the
upper limit of the second commercial laboratoryc reference inter-
val, derived in an internal unpublished study of 30 cats) with con-
current USG < 1.035. Cats that were nonazotemic, with a
UPC < 0.4 and no clinical history of disease (except for dental dis-
ease or degenerative joint disease) were included in the healthy
older cat group. Nonazotemic cats with a clinical history of dis-
ease were excluded from the healthy older cat group.
Statistical Analysis
Using the Mann-Whitney U-test, serum cystatin C concentra-
tions were compared between; hyperthyroid cats which developed
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renal azotemia in the follow up period (pre-azotemic) and those
which remained nonazotemic throughout the follow up period
(nonazotemic), hyperthyroid cats and healthy older cats, and non-
hyperthyroid cats with azotemic CKD and healthy older cats.
Serum cystatin C concentrations in hyperthyroid cats before treat-
ment and at the time of establishment of euthyroidism were com-
pared using the Wilcoxon signed-rank test. Correlations between
baseline serum concentrations of TT4 and cystatin C (in all cats),
and between serum concentrations of creatinine and cystatin C (in
untreated hyperthyroid cats only), were assessed by Spearman’s
correlation coefficient. Data are presented as median [25th, 75th
percentile] and statistical significance was defined as P < .05.
Results
The PETIA for serum cystatin C demonstrated excel-
lent precision and reproducibility (CV <10%) at all
levels tested (Table 1). The assay was linear in the range
0.5–3.5 mg/L (r2 = 0.99) and the limit of blank was
determined to be <0.01 mg/L.
Fifty-five hyperthyroid cats were included in the
study, 21 of which developed azotemia within 4 months
of successful treatment of hyperthyroidism (pre-azote-
mic group). Therefore, there were 34 hyperthyroid cats
included in the nonazotemic group. In addition, 24
healthy older cats (including 1 cat diagnosed with mild
entropion) and 12 cats with azotemic CKD were
recruited to the study. Baseline clinicopathological data
for these 4 groups are shown in Table 2. Pre-azotemic
and nonazotemic hyperthyroid cats were age matched
(Table 2, P = .68), however, the hyperthyroid group
was significantly older than the healthy older cat group
(Table 2, P < .001). There was no significant difference
in the age of the nonhyperthyroid azotemic CKD group
and the healthy older cat group (Table 2, P = .25).
In hyperthyroid cats, sCysC were not different
between the pre-azotemic and azotemic groups at base-
line (1.9 [1.4, 2.3] mg/L versus 1.5 [1.1, 2.2] mg/L
respectively; P = .22, Fig 1), whereas plasma creatinine
concentrations were significantly higher in pre-azotemic
cats compared with nonazotemic hyperthyroid cats
(Table 2, P < .001). Urine specific gravity data were
available in 17 pre-azotemic and 24 nonazotemic hyper-
thyroid cats, and in 23 healthy older cats and 12 azote-
mic CKD cats (Table 2).
Two cats were treated with 2.5 mg methimazole
daily, 22 cats received 5 mg methimazole daily, 25 cats
received 10 mg methimazole daily and 3 cats received
15 mg methimazole daily (mostly divided into 2 doses).
In addition, 1 cat was treated with 15 mg carbimazole
daily (divided into 3 doses) and 2 cats were treated by
thyroidectomy. At the time of establishment of euthy-
roidism, serum TT4 concentrations in the pre-azotemic
and nonazotemic hyperthyroid groups were 13.0, [5.0,
24.9] nmol/L and 10.7, [3.7, 17.9] nmol/L, respectively.
Six (of 21) pre-azotemic and 12 (out of 35) nonazotemic
hyperthyroid cats had a serum TT4 concentration below
the lower limit of the reference interval (7 nmol/L) at
the time of establishment of euthyroidism, however,
evaluation of serum TSH concentrations was not per-
formed to confirm or rule out iatrogenic hypothy-
roidism. sCysC did not change significantly between
baseline and the time of establishment of euthyroidism
(pretreatment 1.8 [1.2, 2.3] mg/L, after treatment 1.6
Table 1. Intra- and interassay coefficients of variation
(CV) at low, medium, and high serum concentrations of
cystatin C calculated using a human particle enhanced
turbidimetric assay.
Cystatin C
Concentration
Intra-assay Variability
(n = 3)
Interassay
Variability (n = 3)
Mean
Cystatin C
Concentration
(mg/L) CV (%)
Mean
Cystatin C
Concentration
(mg/L)
CV
(%)
Low 0.79 1.4 0.80 2.9
Medium 1.60 0.8 1.66 8.2
High 2.97 0.8 3.03 2.7
Table 2. Selected baseline clinicopathological data in initially nonazotemic hyperthyroid cats that developed azote-
mia within 4 months of successful treatment of hyperthyroidism (pre-azotemic), hyperthyroid cats that remained
nonazotemic throughout the study period (nonazotemic), nonhyperthyroid cats with azotemic CKD, and healthy
older cats.
Variable
Hyperthyroid
Nonhyperthyroid Azotemic CKD Healthy Older CatPre-azotemic Nonazotemic
Age (years) 15.1 [12.3, 16.2] 14.8 [12.9, 16.2] 12.5 [11.3, 16.1] 12.0 [10.5, 14.0]
Serum total thyroxine
concentrations (nmol/L)
82.1 [62.4, 117.9] 108.8 [73.0, 177.8] 23.0 [18.6, 27.5] 21.2 [17.6, 24.8]
Serum/plasma blood urea
nitrogen concentrations
(mg/dL)
34.7 [29.7, 46.2] 25.2 [23.0, 31.6] 42.3 [29.7, 58.5] 28.3 [24.9, 34.4]
Serum/plasma creatinine
concentrations (mg/dL)
1.4 [1.1, 1.6] 1.1 [0.9, 1.3] 2.2 [1.9, 2.8] 1.4 [1.2, 1.6]
Urine specific gravity 1.027 [1.020, 1.039] 1.031 [1.019, 1.041] 1.022 [1.017, 1.028] 1.044 [1.034, >1.050]
Normal reference interval for serum total thyroxine concentrations is 7–45 nmol/L.10 Data are presented as median [25th, 75th
percentiles].
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[1.1, 2.4] mg/L; P = .82, Fig 2), whereas plasma crea-
tinine concentrations increased significantly over this
time (1.2 [1.0, 1.4] mg/dL versus 1.7 [1.3, 2.0] mg/dL;
P < .001). If the nonazotemic group was analyzed sepa-
rately, there was still no significant change in sCysC
after treatment (pretreatment 1.5 [1.1, 2.2] mg/L, after
treatment 1.5 [1.0, 2.4] mg/L; P = .86). Similarly, there
was no significant change in sCysC if only the pre-azo-
temic group were analyzed separately (P = .65).
sCysC in healthy older cats ranged from 0.5 mg/L to
2.7 mg/L, and were greater in hyperthyroid cats than
healthy older cats (1.8 [1.2, 2.2] mg/L versus 1.2 [0.8,
1.4] mg/L; P = .001, Fig 3). When considering only
nonazotemic hyperthyroid cats, the sCysC were still
higher than those of healthy older cats (1.5 [1.1, 2.2]
mg/L versus 1.2 [0.8, 1.4] mg/L; P = .017). However,
sCysC were not significantly different between nonhy-
perthyroid cats with azotemic CKD and healthy older
cats (nonhyperthyroid azotemic CKD group 1.5 [1.0,
1.9] mg/L, healthy older group 1.2 [0.8, 1.4] mg/L;
P = .16, Fig 3). Conversely, serum creatinine concentra-
tions were significantly higher in the nonhyperthyroid
azotemic CKD group than the healthy older cat group
(P < .001, Table 2). No nonhyperthyroid azotemic
CKD cats had a sCysC above the highest value
recorded in a healthy older cat (2.7 mg/L). At baseline,
2/21 pre-azotemic and 3/35 nonazotemic hyperthyroid
cats had a sCysC above the highest value observed in
healthy older cats (2.7 mg/L). sCysC were also weakly
positively correlated with plasma creatinine concentra-
tions (rs = 0.320, n = 55; P = .018) and serum TT4
(rs = 0.307, n = 91; P = .005).
Discussion
The human PETIA for serum cystatin C demon-
strated excellent precision and reproducibility and
appeared linear. Binding of the monoclonal anti-cysta-
tin C antibody to feline cystatin C was not definitively
demonstrated by western blotting in this study,
Fig 1. Box and whisker plots showing baseline serum cystatin C
concentrations in a group of hyperthyroid cats which remained
nonazotemic after treatment (n = 34) and initially nonazotemic
hyperthyroid cats which developed azotemia within 4 months of
successful treatment of hyperthyroidism (n = 21). Whiskers repre-
sent the 5th and 95th percentiles and circles represent outliers.
Serum cystatin C concentrations were not significantly different
between the 2 groups (P = .22).
Fig 2. Line chart showing serum cystatin C concentrations in
hyperthyroid cats before treatment (hyperthyroid) and at time of
establishment of euthyroidism (euthyroid). Serum cystatin C con-
centrations were not significantly different between the hyperthy-
roid and euthyroid time points (P = .82).
Fig 3. Box and whisker plots showing serum cystatin C concen-
trations in a group of initially nonazotemic (serum creatinine con-
centration <2.0 mg/dL) hyperthyroid cats (n = 55), healthy
nonazotemic older cats (n = 24, serum creatinine concentration
<1.7 mg/dL) and nonhyperthyroid cats diagnosed with azotemic
CKD (n = 12). Whiskers represent the 5th and 95th percentiles
and circles represent outliers. Serum cystatin C concentrations
were significantly higher in hyperthyroid cats than healthy nona-
zotemic older cats (P = .001). Serum cystatin C concentrations
were not significantly different between the healthy older cat and
nonhyperthyroid azotemic CKD groups (P = .16).
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although biological validity was suggested, based on the
expected, albeit weak, positive correlation between
sCysC and serum creatinine concentrations and TT4.
This suggests that the avian anti-human cystatin C anti-
body does cross-react with feline cystatin C, although
we could not determine how much of the total feline
cystatin C was detected by the human PETIA.
Recently, an alternative PETIA, which utilizes rabbit
anti-human antibodies against cystatin C, was also vali-
dated for use in feline serum in a preliminary study.11
Further studies to compare the sCysC between these 2
assays would be of interest and could help to validate
the PETIA used in this study.
The primary aim of this study was to assess if serum
cystatin C concentrations might be a marker of concur-
rent, but masked, azotemic CKD in hyperthyroidism.
Although a recent study has demonstrated that the
development of azotemia after treatment of hyperthy-
roidism is not associated with a reduced survival time
in cats that are euthyroid after treatment, there is an
association between the development of azotemia and
reduced survival time in cats with iatrogenic hypothy-
roidism.3 Therefore, the identification of hyperthyroid
cats which have concurrent CKD would be helpful
because the development of iatrogenic hypothyroidism
in these cats could lead to a reduced survival time, and
therefore the treatment plan might need to be altered to
avoid hypothyroidism (perhaps by starting on a lower
dose of anti-thyroid medication or giving a lower dose
of radioiodine). Various studies have attempted to iden-
tify reliable markers of CKD in hyperthyroidism,12–16
however, no single reliable test has been identified.
Early studies suggested that measurement of GFR
might be useful in predicting the development of azote-
mia after treatment of hyperthyroidism,17 however,
other studies have suggested that measurement of GFR
alone is not a reliable predictor of this.18,19 Serum crea-
tinine concentrations are likely to be poor markers of
GFR, and hence the presence of concurrent CKD,
partly due to the changes in body muscle mass that
occur in hyperthyroidism. The use of sCysC as a mar-
ker of GFR might be advantageous in hyperthyroidism
because cystatin C is produced by all nucleated cells
rather than just myocytes. One previous study identified
an association between hyperthyroidism and increased
sCysC in cats,6 which could confound the use of sCysC
as a marker of renal function. However, the presence of
concurrent, but masked, azotemic CKD, which in turn
might have increased sCysC, was not fully ruled out in
the aforementioned study. In this study, sCysC were
not significantly different between hyperthyroid cats
with and without concurrent, but masked, azotemic
CKD, therefore sCysC might not be a useful marker of
GFR and renal function in hyperthyroidism. In addi-
tion, the increased sCysC identified in nonazotemic
hyperthyroid cats suggests that sCysC are increased in
hyperthyroid cats independent of the presence of con-
current, but masked, azotemic CKD.
It is likely that the increased sCysC associated with
hyperthyroidism are secondary to increased cellular pro-
duction of cystatin C associated with the
hypermetabolic state. The weak positive correlation that
existed between sCysC and TT4 in this study would
support this conclusion. Increased cellular production
of cystatin C must also outweigh the increased renal
clearance of cystatin C that would be expected in hyper-
thyroidism secondary to elevated GFR.1 Alternatively,
hyperthyroidism could also be associated with increased
renal reabsorption of cystatin C. Cystatin C is usually
freely filtered by the glomeruli and mostly reabsorbed
and catabolized by the proximal tubules of the kidney,
therefore, tubular damage (in CKD) could lead to
decreased tubular reabsorption of cystatin C.4 Other
work from our laboratory has indicated that overall uri-
nary cystatin C excretion (accounting for renal clear-
ance and tubular reabsorption) is decreased in early
CKD (IRIS stage 2 and 3),7 although another study
reported that cats with CKD had increased overall uri-
nary cystatin C excretion.8 Further studies of renal han-
dling of cystatin C in hyperthyroid cats and
nonhyperthyroid cats with azotemic CKD are war-
ranted to ascertain if altered renal reabsorption of cys-
tatin C occurs in these conditions which could
contribute to altered sCysC in these patients.
Based on the results of this study, sCysC also do not
appear to be reliable markers of renal function in non-
hyperthyroid cats with azotemic CKD. The reason why
sCysC do not appear to be a reliable marker of renal
function in nonhyperthyroid cats is, however, unclear
at this time. Although one previous small study indi-
cated that sCysC are increased in cats with azotemic
CKD,8 a subsequent study calculated a reference inter-
val for sCysC from healthy older cats which encom-
passed serum cystatin C concentrations previously
observed in many cats with azotemic CKD.8,20 This
could suggest that the sensitivity of sCysC for the
detection of CKD is poor. Furthermore, 2 more recent
preliminary studies have indicated that there is a poor
correlation between sCysC and GFR11 and the presence
of CKD.21 This could be secondary to altered cellular
production, metabolism, renal reabsorption and elimi-
nation, or elimination of cystatin C from the body via
other mechanisms (for example, through the gastroin-
testinal tract) in CKD. Given the results of our previ-
ous study,7 altered renal reabsorption and elimination
of cystatin C could be contributory to altered sCysC in
CKD and the poor performance of sCysC as a test for
azotemic CKD in cats.
Serum cystatin C concentrations were also assessed
before treatment and at the time of establishment of
euthyroidism, and despite sCysC being increased in
hyperthyroidism in this study, the sCysC did not
decrease after successful treatment. This could reflect a
combination of the opposing effects of treatment of
hyperthyroidism on GFR, which decreases after treat-
ment and thus would cause an increase in sCysC, and
cellular production of cystatin C, which would also
decrease and thus would decrease sCysC. The overall
effect might therefore be that sCysC remain unchanged
after treatment, however, this does not explain why
sCysC are increased in hyperthyroidism overall. As sta-
ted earlier, increased cellular production of cystatin C
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must outweigh the increased renal clearance of cystatin
C that would be expected in hyperthyroidism secondary
to elevated GFR, therefore leading to an elevated
sCysC in hyperthyroid cats overall, when compared
with healthy older cats. Increased cellular production of
cystatin C might occur for a prolonged period in hyper-
thyroid cats after restoration of euthyroidism, which
could account for the lack of a decrease in sCysC up to
the time of establishment of euthyroidism. Further lon-
gitudinal studies evaluating the change in sCysC over a
longer time period after treatment of hyperthyroidism
are warranted to investigate this.
An additional confounding factor in the evaluation
of sCysC after treatment of hyperthyroidism could be
the development of iatrogenic hypothyroidism, because
hypothyroidism is associated with decreased sCysC in
human patients.5 Although some cats had low serum
TT4 concentrations after treatment in this study, unfor-
tunately, assessment of thyroid stimulating hormone
concentrations, to rule out iatrogenic hypothyroidism,
was not possible, due to financial constraints. The
change in sCysC after treatment of hyperthyroidism
remained nonsignificant if cats with subnormal TT4
concentrations after treatment were excluded from the
analysis (data not shown), therefore the effect of iatro-
genic hypothyroidism on sCysC after treatment is unli-
kely to be a significant confounding factor.
A limitation of this study was the lack of GFR mea-
surements in our healthy older cats. Serum creatinine
concentrations remain within the laboratory reference
intervals in experimental models when 75–83% of renal
function has been lost,22 therefore, it is possible that
some of the cats included in the healthy older cat group
and the nonazotemic hyperthyroid group might have
had subclinical, nonazotemic CKD. This could have
confounded the comparison in sCysC between healthy
older cats and nonhyperthyroid cats with azotemic
CKD, and between pre-azotemic and nonazotemic
hyperthyroid cats. It has been speculated that serum
symmetrical dimethylarginine (SDMA) concentrations
are a more sensitive indicator of reduced GFR,23 and
therefore determination of SDMA concentrations might
have allowed us to detect early nonazotemic CKD in
some of the healthy older cats and nonazotemic hyper-
thyroid cats in this study. However, the effect of thyroid
function on SDMA concentrations is currently
unknown, therefore, SDMA could be subject to the
same limitations as creatinine for the determination of
renal function in hyperthyroid cats. Unfortunately,
measurement of GFR was not possible within the first
opinion clinics where these samples were obtained, and
determination of serum SDMA concentrations was not
available commercially at the time of the study.
The samples were obtained over a different time per-
iod for the hyperthyroid cats (2010–2013) and the
healthy older cats and nonhyperthyroid azotemic CKD
cats (2013–2015), therefore the storage time of the sam-
ples (at 80°C) differed between these groups. This
would only have influenced the comparison between
hyperthyroid cats and healthy older cats, however,
given that the findings in this study concur with those
of a previous study,6 it seems unlikely that this was a
significant limiting factor in this study.
A further limitation of this study was that hyperthy-
roid cats were significantly older than healthy older
cats, which could have confounded the results of this
analysis because older cats would have been more likely
to have concurrent nonazotemic CKD, which might
have increased sCysC. However, no significant correla-
tion between age and sCysC was identified in this study
(data not shown) or a previous study.20
In this study, the serum creatinine concentrations
were measured at 2 different commercial laboratories
which had different upper limits of the reference interval
for serum creatinine concentration. As a result, the
inclusion criteria for the hyperthyroid (serum creatinine
concentration <2.0 mg/dL) and the healthy older cat
(serum creatinine concentration <1.7 mg/dL) groups
were different, which could have confounded the com-
parison of sCysC between these groups. However,
patient results should be compared against reference
intervals derived in the same laboratory, since there can
be significant differences in results obtained between
laboratories,24 therefore, it is appropriate to utilize the
laboratory specific upper limit of the reference interval
rather than classify the cats utilizing an arbitrary cutoff
value. Furthermore, higher sCysC have been reported
in hyperthyroid cats compared with healthy cats previ-
ously, which concurs with the findings of our study.6
Finally, samples from healthy older cats and nonhy-
perthyroid cats with azotemic CKD in this study were
up to 3 days old at the time of submission. One previ-
ous study has identified a small, likely clinically insignif-
icant (1.9%), increase in sCysC after storage of samples
at room temperature for a 24 hours period,25 however,
it is currently not known if longer storage would result
in a more clinically relevant increase in sCysC. A previ-
ous study from our laboratory reported that cystatin C
is stable in urine for up to 3 days,7 however stability of
sCysC was not assessed as part of this study. In this
study, submission of samples within a 24 hours period
was not possible from cats in the healthy older cat and
nonhyperthyroid azotemic CKD groups, since these
samples were submitted from first opinion clinics off
site. In addition, the age of the samples in the healthy
older cat group and the nonhyperthyroid azotemic
CKD group at the time of submission was not signifi-
cantly different between the groups, therefore, it is unli-
kely that this would have confounded the comparison
of sCysC between these groups. It is possible that the
inclusion of more older samples in the healthy older cat
group might have confounded the comparison of sCysC
with the hyperthyroid group, however, our findings con-
cur with those of a previous study.6 Comparison of
sCysC between pre-azotemic and nonazotemic hyper-
thyroid cats was not confounded in this study since
these samples were all frozen to 80°C within 6 hours
of sampling. Further studies to examine the effect on
sCysC of storage of samples at room temperature for
longer than a 24 hours period are warranted.
In conclusion, the human PETIA for cystatin C was
successfully validated for use in feline serum, however,
6 Williams et al
the findings of this study indicate that serum cystatin C
concentrations are increased in hyperthyroidism, inde-
pendent of the presence of masked, azotemic CKD,
which might limit the utility of serum cystatin C con-
centrations as a marker of CKD in hyperthyroid cats.
The reason why serum cystatin C concentrations are a
poor marker of GFR in hyperthyroid and nonhyperthy-
roid cats remains unknown.
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